Literature DB >> 18618218

Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma.

Yun-Chao Gao1, Han-Kui Lu, Quan-Yong Luo, Li-Bo Chen, Ying Ding, Rui-Sen Zhu.   

Abstract

Measurement of free plasma metanephrines (metanephrine and normetanephrine), usually performed by high-performance liquid chromatography with electrochemical detection (HPLC-ECD), has been recommended as the single biochemical test of choice for the diagnosis of pheochromocytoma. Alternatively, a widely available, simple means to measure these biomarkers with enzyme immunoassay (EIA) needs to be studied. The aim of this study was to investigate the diagnostic efficacy of such a method in comparison with (131)I-metaiodobenzylguanidine (MIBG) whole body scan (WBS) in patients with pheochromocytoma. We enrolled patients undergoing (131)I-MIBG WBS due to clinical findings suggestive of pheochromocytoma (n = 45), and patients with primary hypertension (n = 36). All subjects had blood tests for free plasma metanephrine (MN) and normetanephrine (NM) with a commercially available EIA kit. WBS was positive in 30 pheochromocytoma patients and negative in 15 refuted ones, with 100% accuracy. The sensitivity, specificity and accuracy of MN and NM in combination (either or both positive) were 96.7%, 86.3% and 90.1%, showing comparable diagnostic performance both to (131)I-MIBG WBS (all p > 0.1), and also to the same markers measured with HPLC-ECD reported in the literature. These results showed that the EIA method may be eligible as an alternative to HPLC-ECD for plasma metanephrine determination in the identification of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618218     DOI: 10.1007/s10238-008-0162-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  18 in total

Review 1.  Imaging of adrenal masses.

Authors:  Mark E Lockhart; J Kevin Smith; Philip J Kenney
Journal:  Eur J Radiol       Date:  2002-02       Impact factor: 3.528

2.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

3.  Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population.

Authors:  Keith L Brain; Jonathan Kay; Brian Shine
Journal:  Clin Chem       Date:  2006-09-21       Impact factor: 8.327

4.  Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen.

Authors:  M Roden; W Raffesberg; W Raber; E Bernroider; B Niederle; W Waldhäusl; S Gasic
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

5.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.

Authors:  G Eisenhofer; J W Lenders; W M Linehan; M M Walther; D S Goldstein; H R Keiser
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

6.  Plasma metanephrines in renal failure.

Authors:  Graeme Eisenhofer; Frans Huysmans; Karel Pacak; MacClellan M Walther; Fred C G J Sweep; Jacques W M Lenders
Journal:  Kidney Int       Date:  2005-02       Impact factor: 10.612

Review 7.  Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour.

Authors:  K Pacak; I Ilias; K T Adams; G Eisenhofer
Journal:  J Intern Med       Date:  2005-01       Impact factor: 8.989

Review 8.  Pheochromocytoma and functional paraganglioma.

Authors:  Heather Yeo; Sanziana Roman
Journal:  Curr Opin Oncol       Date:  2005-01       Impact factor: 3.645

Review 9.  Pheochromocytoma: presentation, diagnosis and treatment.

Authors:  Nicole Reisch; Mariola Peczkowska; Andrzej Januszewicz; Hartmut P H Neumann
Journal:  J Hypertens       Date:  2006-12       Impact factor: 4.844

10.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

View more
  5 in total

Review 1.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 2.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

Review 3.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 4.  The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL).

Authors:  Tomás P Griffin; Delia Bogdanet; Patrick Navin; Grace Callagy; Paula M O'Shea; Marcia Bell
Journal:  Ir J Med Sci       Date:  2018-02-19       Impact factor: 1.568

5.  A Pilot Study for the Neuroprotective Effect of Gongjin-dan on Transient Middle Cerebral Artery Occlusion-Induced Ischemic Rat Brain.

Authors:  Yun-Young Sunwoo; Sang In Park; Yong-An Chung; Jisoo Lee; Moon-Seo Park; Kyung-Sool Jang; Lee-So Maeng; Dong-Kyu Jang; Ruth Im; Yu Jin Jung; Soon A Park; Eun-Sun Kang; Min-Wook Kim; Young-Min Han
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-06       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.